SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a ...
Brazil Phase 2 Pulmonary Long-Hauler clinical trial of COVI-MSC is now authorized to proceed. The study will compare therapy using mesenchymal stromal cells to placebo (and standard of care) in 60 ...
NeuroScientific Biopharmaceuticals Limited (ASX:NSB), an innovative Australian biotechnology company developing novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback